This report covers the 68 geographical markets and provides an Excel-based forecast model for the Pulmonary Arterial Hypertension market.
Across the 68 markets, sales in the PAH market were $10.1 billion in 2024, growing to $17.9 billion in 2034.
The seven major markets (US, France, Germany, Italy, Spain, UK, and Japan) represent approximately 24.5% and 48.0% in 68-market sales in 2024 and 2034, respectively.
Across the 68 markets, sales in the PAH market were $10.1 billion in 2024, growing to $17.9 billion in 2034.
The seven major markets (US, France, Germany, Italy, Spain, UK, and Japan) represent approximately 24.5% and 48.0% in 68-market sales in 2024 and 2034, respectively.
Scope
- This publication is an expanded version of the Excel model containing the patient-based forecast sales for PAH, covered in the analyst’s report “Pulmonary Arterial Hypertension: Seven-Market Drug Forecast and Market Analysis to 2034”, published in June 2025.
- In addition to patient based forecast sales data for the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan), this report contains sales forecast extrapolations for an additional 60 geographical markets (60M), totaling 68 markets (68M).
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the 7MM PAH therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM PAH therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Table of Contents
1 Executive Summary
2 Appendix
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc
- Acceleron Pharma Inc
- Actelion
- Amgen Inc
- Bayer AG
- Bristol Myers Squibb
- Eli Lilly and Co
- Entera Bio Ltd
- Gilead Sciences Inc
- GlaxoSmithKline
- Johnson & Johnson
- Merck & Co Inc
- Novartis International AG
- Pfizer Inc
- Roche Holding AG
- Sanofi
- Teva Pharmaceutical Industries Ltd
- UCB S.A.